Regeneron Pharmaceuticals’ (NASDAQ:REGN) Buy Rating Reaffirmed at UBS AG
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reissued by equities research analysts at UBS AG in a note issued to investors on Friday, 99wallstreet.com reports. They presently have a $535.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $489.00. UBS AG’s price target would suggest a potential upside of 14.13% from the stock’s previous close.
A number of other analysts also recently commented on REGN. Jefferies Group LLC restated a “hold” rating and issued a $357.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 12th. Vetr cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target for the company. in a report on Monday, April 24th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price target for the company in a report on Thursday, April 27th. BMO Capital Markets reaffirmed a “hold” rating and issued a $421.00 price target (up previously from $412.00) on shares of Regeneron Pharmaceuticals in a report on Friday, May 5th. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $380.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $477.91.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded up 0.35% during mid-day trading on Friday, reaching $468.76. The company had a trading volume of 771,168 shares. The stock has a 50 day moving average of $499.60 and a 200-day moving average of $421.63. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $543.55. The company has a market capitalization of $49.49 billion, a price-to-earnings ratio of 56.74 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the prior year, the business earned $2.82 earnings per share. The company’s revenue was up 21.2% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals will post $13.63 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals’ (NASDAQ:REGN) Buy Rating Reaffirmed at UBS AG” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/06/regeneron-pharmaceuticals-nasdaqregn-buy-rating-reaffirmed-at-ubs-ag.html.
In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the completion of the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $1,350,000. The disclosure for this sale can be found here. Insiders have sold 59,396 shares of company stock valued at $28,484,734 in the last three months. Insiders own 10.40% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 1 shares in the last quarter. Concert Wealth Management Inc. boosted its stake in Regeneron Pharmaceuticals by 0.4% in the first quarter. Concert Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 3 shares in the last quarter. Cleararc Capital Inc. boosted its stake in Regeneron Pharmaceuticals by 0.3% in the first quarter. Cleararc Capital Inc. now owns 1,850 shares of the biopharmaceutical company’s stock valued at $717,000 after buying an additional 5 shares in the last quarter. Regentatlantic Capital LLC boosted its stake in Regeneron Pharmaceuticals by 0.9% in the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 1.4% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 750 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 10 shares in the last quarter. 66.79% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.